290 related articles for article (PubMed ID: 30468137)
21. Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visit.
Fendrick AM; Brixner D; Rubin DT; Mease P; Liu H; Davis M; Mittal M
J Manag Care Spec Pharm; 2021 Aug; 27(8):1086-1095. PubMed ID: 33843252
[No Abstract] [Full Text] [Related]
22. Effect of antidepressant switching between nortriptyline and escitalopram after a failed first antidepressant treatment among patients with major depressive disorder.
Köhler-Forsberg O; Larsen ER; Buttenschøn HN; Rietschel M; Hauser J; Souery D; Maier W; Farmer A; McGuffin P; Aitchison KJ; Uher R; Mors O
Br J Psychiatry; 2019 Aug; 215(2):494-501. PubMed ID: 30698114
[TBL] [Abstract][Full Text] [Related]
23. Alterations in dorsal and ventral posterior cingulate connectivity in APOE
Kerestes R; Phal PM; Steward C; Moffat BA; Salinas S; Cox KL; Ellis KA; Cyarto EV; Ames D; Martins RN; Masters CL; Rowe CC; Sharman MJ; Salvado O; Szoeke C; Lai M; Lautenschlager NT; Desmond PM
BJPsych Open; 2015 Oct; 1(2):139-148. PubMed ID: 27703739
[TBL] [Abstract][Full Text] [Related]
24. Hypothyroidism in patients with bipolar I disorder treated primarily with lithium.
Fagiolini A; Kupfer DJ; Scott J; Swartz HA; Cook D; Novick DM; Frank E
Epidemiol Psichiatr Soc; 2006; 15(2):123-7. PubMed ID: 16865933
[TBL] [Abstract][Full Text] [Related]
25. Probability of major depression diagnostic classification using semi-structured versus fully structured diagnostic interviews.
Levis B; Benedetti A; Riehm KE; Saadat N; Levis AW; Azar M; Rice DB; Chiovitti MJ; Sanchez TA; Cuijpers P; Gilbody S; Ioannidis JPA; Kloda LA; McMillan D; Patten SB; Shrier I; Steele RJ; Ziegelstein RC; Akena DH; Arroll B; Ayalon L; Baradaran HR; Baron M; Beraldi A; Bombardier CH; Butterworth P; Carter G; Chagas MH; Chan JCN; Cholera R; Chowdhary N; Clover K; Conwell Y; de Man-van Ginkel JM; Delgadillo J; Fann JR; Fischer FH; Fischler B; Fung D; Gelaye B; Goodyear-Smith F; Greeno CG; Hall BJ; Hambridge J; Harrison PA; Hegerl U; Hides L; Hobfoll SE; Hudson M; Hyphantis T; Inagaki M; Ismail K; Jetté N; Khamseh ME; Kiely KM; Lamers F; Liu SI; Lotrakul M; Loureiro SR; Löwe B; Marsh L; McGuire A; Mohd Sidik S; Munhoz TN; Muramatsu K; Osório FL; Patel V; Pence BW; Persoons P; Picardi A; Rooney AG; Santos IS; Shaaban J; Sidebottom A; Simning A; Stafford L; Sung S; Tan PLL; Turner A; van der Feltz-Cornelis CM; van Weert HC; Vöhringer PA; White J; Whooley MA; Winkley K; Yamada M; Zhang Y; Thombs BD
Br J Psychiatry; 2018 Jun; 212(6):377-385. PubMed ID: 29717691
[TBL] [Abstract][Full Text] [Related]
26. Changes in acute headache medication use and health care resource utilization: Results from a randomized, double-blind, placebo-controlled clinical trial evaluating galcanezumab in adults with treatment-resistant migraine (CONQUER).
Ambrosini A; Estemalik E; Pascual J; Rettiganti M; Stroud C; Day K; Ford J
J Manag Care Spec Pharm; 2022 Jun; 28(6):645-656. PubMed ID: 35451858
[No Abstract] [Full Text] [Related]
27. Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study.
Siderowf A; Concha-Marambio L; Lafontant DE; Farris CM; Ma Y; Urenia PA; Nguyen H; Alcalay RN; Chahine LM; Foroud T; Galasko D; Kieburtz K; Merchant K; Mollenhauer B; Poston KL; Seibyl J; Simuni T; Tanner CM; Weintraub D; Videnovic A; Choi SH; Kurth R; Caspell-Garcia C; Coffey CS; Frasier M; Oliveira LMA; Hutten SJ; Sherer T; Marek K; Soto C;
Lancet Neurol; 2023 May; 22(5):407-417. PubMed ID: 37059509
[TBL] [Abstract][Full Text] [Related]
28. Pleiotropic genes in psychiatry: Calcium channels and the stress-related FKBP5 gene in antidepressant resistance.
Fabbri C; Corponi F; Albani D; Raimondi I; Forloni G; Schruers K; Kasper S; Kautzky A; Zohar J; Souery D; Montgomery S; Cristalli CP; Mantovani V; Mendlewicz J; Serretti A
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Feb; 81():203-210. PubMed ID: 28989100
[TBL] [Abstract][Full Text] [Related]
29. Seasonal affective disorder and non-seasonal affective disorders: results from the NESDA study.
Winthorst WH; Roest AM; Bos EH; Meesters Y; Penninx BWJH; Nolen WA; de Jonge P
BJPsych Open; 2017 Jul; 3(4):196-203. PubMed ID: 28904813
[TBL] [Abstract][Full Text] [Related]
30. Burden of Illness in Type 2 Diabetes Mellitus.
Cannon A; Handelsman Y; Heile M; Shannon M
J Manag Care Spec Pharm; 2018 Sep; 24(9-a Suppl):S5-S13. PubMed ID: 30156443
[TBL] [Abstract][Full Text] [Related]
31. Predictive factors for hyperglycaemic progression in patients with schizophrenia or bipolar disorder.
Kusumi I; Arai Y; Okubo R; Honda M; Matsuda Y; Matsuda Y; Tochigi A; Takekita Y; Yamanaka H; Uemura K; Ito K; Tsuchiya K; Yamada J; Yoshimura B; Mitsui N; Matsubara S; Segawa T; Nishi N; Sugawara Y; Kako Y; Shinkawa I; Shinohara K; Konishi A; Iga J; Hashimoto N; Inomata S; Tsukamoto N; Ito H; Ito YM; Sato N
BJPsych Open; 2018 Nov; 4(6):454-460. PubMed ID: 30450224
[TBL] [Abstract][Full Text] [Related]
32. A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough?
Dodd S; Bauer M; Carvalho AF; Eyre H; Fava M; Kasper S; Kennedy SH; Khoo JP; Lopez Jaramillo C; Malhi GS; McIntyre RS; Mitchell PB; Castro AMP; Ratheesh A; Severus E; Suppes T; Trivedi MH; Thase ME; Yatham LN; Young AH; Berk M
World J Biol Psychiatry; 2021 Sep; 22(7):483-494. PubMed ID: 33289425
[TBL] [Abstract][Full Text] [Related]
33. When are breakthrough therapies cost-effective?
Olchanski N; Lin PJ; Yeh WS; Kowal S; Cohen JT
J Manag Care Spec Pharm; 2022 Jul; 28(7):732-739. PubMed ID: 35737862
[No Abstract] [Full Text] [Related]
34. Results of the European Group for the Study of Resistant Depression (GSRD) - basis for further research and clinical practice.
Bartova L; Dold M; Kautzky A; Fabbri C; Spies M; Serretti A; Souery D; Mendlewicz J; Zohar J; Montgomery S; Schosser A; Kasper S
World J Biol Psychiatry; 2019 Jul; 20(6):427-448. PubMed ID: 31340696
[No Abstract] [Full Text] [Related]
35. The effect of second-generation antipsychotics on hippocampal volume in first episode of psychosis: longitudinal study.
Bodnar M; Malla AK; Makowski C; Chakravarty MM; Joober R; Lepage M
BJPsych Open; 2016 Mar; 2(2):139-146. PubMed ID: 27703766
[TBL] [Abstract][Full Text] [Related]
36. Treatment-resistant depression and peripheral C-reactive protein.
Chamberlain SR; Cavanagh J; de Boer P; Mondelli V; Jones DNC; Drevets WC; Cowen PJ; Harrison NA; Pointon L; Pariante CM; Bullmore ET
Br J Psychiatry; 2019 Jan; 214(1):11-19. PubMed ID: 29764522
[TBL] [Abstract][Full Text] [Related]
37. Overview of alopecia areata for managed care and payer stakeholders in the United States.
King B; Pezalla E; Fung S; Tran H; Bourret JA; Peeples-Lamirande K; Takiya L; Napatalung L
J Manag Care Spec Pharm; 2023 Jul; 29(7):848-856. PubMed ID: 37219075
[TBL] [Abstract][Full Text] [Related]
38. An online survey among US patients with immune-mediated conditions: Attitudes about biosimilars.
Gibofsky A; Jacobson G; Franklin A; O'Hara-Levi S; Peyrin-Biroulet L; McGrath M; McCabe D
J Manag Care Spec Pharm; 2023 Apr; 29(4):343-349. PubMed ID: 36989450
[No Abstract] [Full Text] [Related]
39. A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping.
Fabbri C; Kasper S; Kautzky A; Zohar J; Souery D; Montgomery S; Albani D; Forloni G; Ferentinos P; Rujescu D; Mendlewicz J; Uher R; Lewis CM; Serretti A
Transl Psychiatry; 2020 Feb; 10(1):50. PubMed ID: 32066715
[TBL] [Abstract][Full Text] [Related]
40. Predicting early transition from sub-syndromal presentations to major mental disorders.
Cross SPM; Scott J; Hickie IB
BJPsych Open; 2017 Sep; 3(5):223-227. PubMed ID: 28959452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
